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Abstract
Asthma is a common, chronic inflammatory airways disease characterized by a clinical syndrome of bronchial
hyperresponsiveness, inflammation, and reversible airflow obstruction. Individuals with asthma can vary widely
in clinical presentation, severity, and pathobiology. The incident factors, pathogenesis, prognosis, and treatment
of asthma remain incompletely understood. Utilizing measurable characteristics of asthmatic patients, including
demographic, physiologic, and biologic markers, can however identify meaningful phenotypic categories in asthma.
Identification of these phenotypes may help improve precision therapeutics targeted toward an individual’s’ disease,
and may identify strategies for preventing progression of disease severity.
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Background
Asthma is a chronic inflammatory disease of the airways.
Individuals with asthma may experience recurrent wheez-
ing, dyspnea, chest tightness, and cough. These symptoms
reflect episodes of reversible airflow obstruction, which
may remit spontaneously or with treatment. Over time,
many asthmatics experience progressive airway remodeling,
leading to an incompletely reversible, or fixed, airflow
obstruction. Further, inflammation in the asthmatic
airway induces airway bronchial hyper-responsiveness
to a variety of allergic, infectious, or irritant stimuli.
Public health impact of asthma
Asthma is a very common chronic disorder. Asthma
severity can range from intermittent to severe; more
severe asthma is associated with significant morbidity
and mortality. Further, asthma prevalence is increasing
with time [1], perhaps due to better recognition and
phenotyping. It is estimated that, in the United States
in 2013, asthma affected 16.5 million adults and 6.1
million children, reflecting 8.3% and 7.0% of the popu-
lation, respectively [2]. Approximately half of those
individuals experienced an asthma attack, which is
defined as sudden worsening of asthma symptoms due
to bronchoconstriction, and when severe, hyperinflation
and “air trapping” [3]. Asthma is the leading cause of
absenteeism in children in the United States, causing ap-
proximately 50% of children to miss at least one school
day each year, and one in three adults to miss at least 1
day of work. Three out of five asthmatics are forced to
limit their usual activities because of this disease.
Asthma remains a prevalent disease worldwide. Estimates
from worldwide analyses such as the Global Burden of
Disease Study from the Forum of International Respiratory
Societies suggest that asthma affects at least 235–334
million individuals [4, 5]. Using data from the Inter-
national Study of Asthma and Allergies in Childhood
surveys, approximately 14% of the world’s children
suffer from asthma in any given year. Latin American
and English-speaking countries of Australiasia, Europe,
North America, and South America have the highest
prevalence of childhood asthma, estimated at over 20%
[6]. Reported asthma symptoms in children increased
from 1993 to 2003 in low- and middle-income countries.
Estimates of asthma prevalence in adults are more difficult
to obtain. Approximately 8.6% of adults worldwide between
the ages of 18–45 have asthma symptoms. The morbidity
and mortality burden of disease, however, disproportion-
ately affects older adults [5].
Global measures of disability rank asthma 14th in
number of years lost to asthma-associated morbidity and
mortality [7]. This most significantly affects individuals
in some countries of Europe, Central and South America,
Africa, and Austrailasia. Annually in the United States,
asthma accounts for approximately 15.5 million outpatient
health care visits, 1.8 million emergency department visits,
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and 439,000 hospitalizations, costing the US $56
billion each year, or roughly $3259 per person [8]. In a
European study from 2011, the estimated total cost of
asthma in adolescents and adults was €19.3 billion [9].
In the Asia-Pacific region, the estimated direct and in-
direct cost of asthma per person range from $184 to
1189. In the United States in 2013, 3630 individuals
died from asthma, or nine people per day [1, 8]. These
data suggest asthma is often poorly controlled, despite
the availability of pharmacologic therapies that are
recommended in National and International Asthma
Guidelines [10–12].
Development of asthma
An individual’s susceptibility to the development of
asthma, or to severity of asthma, are likely determined
by an interaction of host or genetic characteristics that
interact with environmental exposures. For example,
specific genotypes can confer susceptibility to developing
wheezing with rhinovirus exposure [13], atopy, or
responsiveness to bronchodilator therapy [14, 15].
Currently, there are a number of genes that are associated
with asthma susceptibility [16]. An important question in
whether these or different genes influence asthma pro-
gression and severity. Environmental exposures, including
prenatal influences [17], allergens [18, 19], respiratory in-
fections [20–22], cigarette smoke [23], and air pollution
[24] are implicated in the development of asthma. Cumu-
lative environmental exposures may lead to persistent,
progressive disease with potentially irreversible changes in
lung structure and function. These concepts are illustrated
in Fig. 1 which describes the interaction between genetics
and environment in the development and progression of
asthma. Because of differences in the influence of genes
and environment, there is a wide range of disease hetero-
geneity and severity in asthma.
Assessment of asthma
All that wheezes is not asthma, and all asthma does not
wheeze. Accurate diagnosis of asthma is important, as treat-
ment will benefit both morbidity and mortality from this
disorder. As many non-asthmatic diseases have overlapping
clinical findings with asthma, accuracy of clinical diagnosis
is critical for planning appropriate treatment strategies. The
Global Strategy for Asthma Management and Prevention
2015 report update [12] and the National Institutes of
Health Guidelines for the Diagnosis and Management of
Asthma Expert Panel Report-3 [10] provide recommenda-
tions for the diagnosis of asthma. In addition to obtaining a
detailed history of symptoms and physical exam, these
guidelines suggest obtaining studies of lung function such
as spirometry to measure forced expiratory volume in 1 s
(FEV1) and forced vital capacity (FVC) measurement, as
the FEV1/FVC ratio objectively measures airflow obstruc-
tion. Additional pulmonary function testing such as diffus-
ing capacity, lung volumes, or bronchoprovocation studies
to support or refute the asthma diagnosis. Comorbidities
and alternate diagnoses should be evaluated when symp-
toms are atypical or not responding to therapy.
Treatment of non-severe asthma
Goals of asthma treatment are multifaceted. A combination
of controller and rescue therapy for asthma usually allows
an individual to achieve and maintain control of asthma
symptoms. Control of asthma should confer a normal day-
to-day activity level, including exercise capacity. Treatment
of asthma may prevent the development of irreversible
airflow limitation and allow maintenance of best possible
pulmonary function. Adequate control of asthma, by defin-
ition, should prevent exacerbations and limit mortality due
to asthma [10, 12]. Importantly, treatment should also iden-
tify and minimize medication side effects.
The Global Strategy for Asthma Management and Pre-
vention 2015 report update [12] and the National Institutes
Fig. 1 Gene-environment interactions in susceptibility and severity of asthma
Carr and Bleecker World Allergy Organization Journal  (2016) 9:41 Page 2 of 8
of Health Guidelines for the Diagnosis and Management of
Asthma Expert Panel Report-3 [10] also provide a
framework for the treatment of asthma. These guidelines
emphasize evaluation of impairment and risk, with on-
going assessment of control. The domains of impairment
and control focus on assessment of symptom frequency,
frequency of use of rescue medications, impact on activity
levels, and lung function. The risk domain identifies risk
of exacerbations and adverse outcomes utilizing an indi-
viduals’ history of exacerbations and lung function, with a
goal of prevention of future exacerbations or fixed airflow
limitation. The severity of asthma as measured through
these domains is then used to guide treatment.
A stepwise approach to therapy is recommended, which
highlights use of controller medications, particularly
inhaled corticosteroids, then titrating doses or adding
additional therapies as needed to achieve the necessary
level of symptom control. At every level, assessment of
proper inhaler device techniques, adherence to therapy,
environmental control, and use of rescue inhalers for
quick relief of sudden symptoms are recommended.
Well recognized, however, is the inter-individual vari-
ability in response to each treatment [25, 26], reflecting
the heterogeneity of disease which exists across severity
groups.
Severe asthma
Task force definitions of severe asthma
The American Thoracic Society and European Respiratory
Society released a Task Force document in 2014 entitled
“International ERS/ATS Guidelines on Definition, Evalu-
ation and Treatment of Severe Asthma [11].” The pur-
poses of this document include defining severe asthma
and treatment-resistant asthma; discussing phenotypes of
severe asthma with respect to genetics, natural history,
pathobiology, and physiology; outlining evaluation of a
patient with severe asthma; and providing recommenda-
tions for treatment of severe asthma in children and adults.
Assuming asthma diagnosis is accurate and comorbidities
are being addressed, severe asthma is defined as asthma
that requires treatment with guidelines-suggested medi-
cations such as high dose inhaled corticosteroids and a
second controller for the previous year, and/or systemic
corticosteroids for at least half of the previous year, to
prevent it from becoming ‘uncontrolled’ or which re-
mains ‘uncontrolled’ despite this therapy. Uncontrolled
asthma is defined as the presence at least one of the
following characteristics: persistently poor symptom
control, two or more exacerbations requiring bursts of
systemic corticosteroids in the preceding year, at least
one serious exacerbation requiring hospitalization in
the previous year, or chronic airflow limitation of FEV1 <
80% predicted with FEV1/FVC ratio less than the lower
limit of normal [11].
Evaluation of patients with severe asthma
Individuals with severe asthma should undergo a careful
systematic assessment to confirm this diagnosis. Lung func-
tion testing is utilized to confirm airflow obstruction and to
measure reversibility or variability of airflow obstruction.
Bronchoprovocation testing, such as with methacholine
inhalation or exercise, may also be utilized. Medication
noncompliance or poor inhaler technique can be iden-
tified in many severe asthmatics [27, 28]. Atopy and
unregulated allergic exposures, such as ongoing house
dust mite or cockroach exposure in an individual with
sensitization to these antigens, may contribute to severe
asthma, particularly in children [29]. Chronic rhinosinusitis
is a very common comorbidity of asthma and contributes
to disease severity [30, 31]. Obesity, obstructive sleep apnea,
and psychological factors may contribute to asthma severity
or perception [11, 32]. Symptomatic gastro-esophageal
reflux disease is common in asthmatics, but the effect
of treatment on asthma control or severity is currently
unclear. The contribution of tobacco smoke exposure,
hormones, and medication use should be carefully con-
sidered, as avoidance of the offending agent can confer
major benefits on asthma control [11].
Treatment of patients with severe asthma
Inhaled corticosteroids remain the mainstay of asthma
treatment, particularly in mild to moderate disease. By
definition, those individuals with severe asthma require
high doses of corticosteroid to control disease, and often
remain symptomatic despite this therapy. Further, a subset
of severe asthmatics is relatively corticosteroid insensitive,
with relative or complete lack of clinical improvement from
treatment with inhaled or systemic corticosteroids. While
corticosteroid insensitivity seems more common in those
with vitamin D deficiency or obesity, eosinophilic or type-2
inflammation-high asthma may have a relative benefit from
steroids when compared to those with non-eosinophilic,
non-type-2 inflammation [33].
Other controller therapies may benefit some individuals
with severe asthma. Beta-agonists provide smooth muscle
relaxation and bronchodilation through beta-adrenergic re-
ceptors. While short acting and long acting beta-agonists
are used in asthma, concern that these drugs may contrib-
ute to asthma treatment failure, particularly in individuals
with genetic differences in the beta-adrenergic receptor,
may impact use [15]. However, recent results of United
States Food and Drug Administration-mandated safety
studies with inhaled corticosteroid-long acting beta agonist
combination therapy do not show evidence of adverse
effects [34, 35]. Leukotriene modifiers may benefit severe
asthmatics with aspirin exacerbated respiratory disease.
Anticholinergics block smooth muscle contraction through
inhibition of the muscarinic receptor-3. The long-acting
muscarinic antagonist Tiotriopum bromide has shown
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benefit some individuals with severe asthma [36, 37].
These treatments, as well as potential future approaches,
are highlighted in Fig. 2.
Biological therapeutics, those with a specific pathobiolo-
gical target, have been and continue to be developed for
use in severe asthma with particular phenotypes. Three
are available currently in the United States for clinical use.
Omalizumab, a monoclonal anti-Immunoglobulin E anti-
body, may be beneficial for some allergic asthmatics un-
controlled on therapy [38]. Mepolizumab and Reslizumab,
both monoclonal anti-IL5 antibodies, reduce asthma
exacerbations in those with severe eosinophilic asthma
[39, 40], Different treatments, particularly for those
with both-type 2 and non-Th2 inflammatory asthma,
are under active development [41–43].
Asthma heterogeneity
With a developing understanding of the marked hetero-
geneity within the disease of asthma, we hypothesize,
and expect to confirm, that the heterogeneity of asthma
is attributable largely to individuals’ genetic and epigen-
etic variability, mediated by certain environmental ex-
posures. Environmental exposures are highly dependent
on regional characteristics with varying climatic conditions,
geography and population distributions. This variability in
turn drives the immunologic mechanisms, or endotype,
that confer the pathobiological and physiologic characteris-
tics of asthma, the phenotype, as measured in the clinical
setting. Importantly, our understanding of this variability
and the mechanisms causing this disease may facilitate the
development of interventions for primary prevention, dis-
ease modification, and precision therapeutics.
Hypothesis-driven univariate approaches to phenotyping
have been utilized to clarify differences among groups of
asthmatics. This type of approach defines groups based on
the presence or quality of one variable, which is chosen to
support testing a specific hypothesis. Disease severity may
be the most straightforward, if not oversimplified, way of
delineating disease phenotype. As anticipated, and likely as
a result of the definitions of severe asthma, groups with
severe asthma can be distinguished from non-severe
asthmatics in terms of disease duration, symptomatology,
health care utilization, lung function, and comorbidities
[44–47]. However, it is well recognized that disease hetero-
geneity is present and vitally important among these sever-
ity classes, particularly among the more severe asthmatics
[48] wherein cellular characteristics and airway remodeling
have been long shown to confer different physiologic sub-
types. Phenotypic characterization solely by disease severity
therefore lacks the granularity to understand and delineate
subtypes of asthma.
Other clinical characteristics have been assessed using
hypothesis-driven univariate approaches. Reduction in
mid forced expiratory flow rates (FEF25-75), as well as
in FEV1, have been shown to be independently associ-
ated with markers of asthma severity, including ICU ad-
missions, persistent or nocturnal symptoms, peripheral
blood eosinophilia, and bronchial hyperreactivity [49]. A
striking relationship between age and the probability of
severe asthma was identified, particularly in men, in-
creasing with duration of disease and from ages 18 to 45
[47, 50]. Airway mast cell phenotype and activation may
contribute to phenotype and clinical characteristics. Indeed,
mast cells containing both tryptase and chymase have been
identified as the predominant phenotype in patients with
severe asthma, whereas mast cells containing only
tryptase are identified in biopsies from individuals with
mild disease [51].
Inflammatory mediators within the airway may also be
used for disease phenotyping. These inflammatory markers,
present in sputum supernatant or bronchoalveolar lavage,
may be related to cellular patterns that then relate to
clinical phenotypes [52], or to disease characteristics
such as eosinophilia, neutrophilia, airway bronchial
Fig. 2 European respiratory society and American thoracic society task force; severe or therapy-resistant asthma: therapy
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hyperresponsiveness, and bronchodilator response [53].
Interestingly, when examining broncoalveolar lavage of
children with asthma, while markers such as IL-13 and
IL-6 can differentiate asthmatics from controls, and other
cytokines can distinguish moderate from severe asthma,
severe asthma itself does not have a clearly TH1 or TH2
inflammatory pattern [54]. This further underscores the
heterogeneity of severe asthma.
Finally, technology to measure gene expression such
as microarray and RNA-seq can provide insight into ab-
normally expressed pathways. Bronchial airway epithelial
gene expression patterns were assessed in relationship to
the clinical biomarker fractional exhaled nitric oxide
(FeNO). Using a subset of genes that correlated with FeNO,
subject clusters can be identified as having distinct clinical
and molecular characteristics [55].
Model-free multivariate (Unbiased Cluster) approaches
Unbiased approaches to phenotyping utilize computer
algorithms to evaluate hypothesis-free relationships among
many clinical and biological characteristics. The resultant
clusters, because they were created in an unbiased manner,
can provide novel insights into asthma phenotypes.
The National Institutes of Health-sponsored Severe
Asthma Research Program (SARP) enrolled and carefully
assessed large cross-sectional cohorts of mild, moderate,
and severe asthmatic adults and children. Unsupervised
hierarchical cluster analysis performed on clinical and
physiologic data from ~700 adult asthmatics in the
SARP cohort identified five clusters of asthmatic sub-
jects (Fig. 3) [47, 56]. Clinical clusters 1, 2, and 4 contain
early onset, atopic asthmatics of increasing disease severity
and worsening lung function. Cluster 3 is characterized by
older, obese women with late-onset non-atopic asthma,
with moderate lung function deficits and frequent exacer-
bations. Cluster 5 is characterized by later onset non-atopic
asthma with more severe, irreversible airflow obstruction
and high health care utilization. The most influential
variables in forming these clusters include gender, age
of asthma onset, asthma duration, use of inhaled beta-
agonists and corticosteroids, and lung function pre-
and post-bronchodilator administration [57].
With an unrelated cohort, investigators from Leicester
likewise examined adult asthmatics through cluster ana-
lysis, revealing similar phenotypes of benign (mild) asthma,
early onset atopic asthma, early onset symptom predomin-
ant asthma, obese non-eosinophilic asthma, and late onset
inflammation predominant asthma [58]. The reproducible
findings of these and other unrelated cohorts support these
phenotypes as relevant [44, 59, 60].
Unsupervised cluster analyses were also performed on
161 subjects in the pediatric asthmatic cohort from SARP
[61]. Four clusters were identified. Cluster 1 consists mainly
of mild, later onset, less atopic asthma with normal lung
function. Clusters 2, and 3 represent the spectrum of early
onset, atopic asthma with increasing severity and worsening
lung function. Cluster 4 identified a subset with more
severe, fixed airflow obstruction and the highest health care
utilization. These clusters have similarities to those seen in
the adult SARP analyses.
Unsupervised cluster analysis was similarly utilized by
researchers from the Trousseau Asthma Program in Paris,
Fig. 3 Severe asthma research program clinical clusters
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France [62] to identify phenotypic clusters in a pediatric
severe asthma cohort of 315 subjects. Clinical and in-
flammatory markers were included in these analyses.
Three clusters were identified: one of mild asthma, one
of highly atopic asthma with eosinophilia and severe
exacerbations, and one of higher body mass index, neu-
trophilia and more severe airflow obstruction. Despite
the differences between the SARP and Trousseau co-
horts, the clusters have features that generally overlap:
SARP cluster 1 similar to the “mild” cluster, SARP clus-
ter 3 to the “atopic severe” cluster and SARP cluster 4
to the “airflow obstruction” cluster.
Sputum cellular characteristics can identify patterns of
airway inflammation and may have clinical utility. For
example, individuals with sputum eosinophilia are likely
to derive benefit from use of inhaled corticosteroids [63].
Phenotyping by cellular characteristics also can identify
groups with differences in clinical and inflammatory
markers. Airway neutrophilia has been associated with
severe asthma defined by low lung function and use of
high dose inhaled or oral corticosteroids [64]. Similarly
in the SARP cohort, when using pre-defined normal
and elevated cell counts, in the absence of cluster analysis,
cellular asthmatics with elevated sputum eosinophilia (≥2%)
and neutrophilia (≥ 40%) tended to have lower lung func-
tion, increased symptoms and health care utilization when
compared with others [52].
A further examination of the adult SARP data integrated
inflammatory cellular measures with the clinical variables
in an unsupervised cluster analysis. Four phenotypic clus-
ters were identified, which represented a severity spectrum
from those with mild-to-moderate allergic disease (SARP
clusters 1,2), having predominantly paucigranulocytic or
eosinophilic sputum, to those with moderate-to-severe
asthma or impaired lung function, most of whom had
significant sputum neutrophilia with or without significant
eosinophilia (SARP clinical clusters 3, 4, and 5) [65]. Im-
portantly, the more inflammatory and severe clusters had
markedly increased asthma medication use and health
care utilization, including bursts of systemic corticoste-
roids and hospitalizations [57, 65].
Data collected from longitudinal cohorts can also be
used for unsupervised cluster analyses, leveraging the
power of the longitudinal design to provide insight into
the variable patterns of disease over time. Analyses of
pediatric birth cohorts have identified clusters of wheeze,
atopy, or other characteristics that are associated with
risk for asthma-related outcomes into the teenaged years.
For example, the Avon Longitudinal Study of Parents And
Children (ALSPAC) study collected data on wheezing at
multiple time points from birth to age 7 years, for 6265
children in the United Kingdom [66]. The authors utilized
wheeze data in latent class analysis to describe patterns of
early wheeze, then examined clinical characteristics of
individuals in these classes. Associations with atopy, airway
hyper-responsiveness, and lung function abnormalities were
seen in intermediate and late onset wheezing. These
findings were similar to those from analyses of the
Dutch Prevention and Incidence of Asthma and Mite
Allergy (PIAMA) study, a multicenter birth cohort that
enrolled 4146 pregnant women [67]. A latent class analysis
of the PIAMA data identified 5 phenotypes of child-
hood wheeze, similar to those seen in ALSPAC [68].
The ALSPAC cohort was again assessed after age 16;
latent class analysis identified early onset persistent
wheeze to confer risk of lung function abnormalities.
The Manchester Asthma and Allergy Study is an unse-
lected birth cohort of over 1000 children with periodic
lung function and assessments of atopy and other clinical
characteristics. Principal component analysis was per-
formed using twenty one variables available at up to 5
years of age; patterns of wheeze and cough components
were significant contributing components to the groups
[69]. With the availability of 8-year old data for this
cohort, a latent class analysis was performed, which
identified differences in lung function trajectories over
time among the classes, as well as more severe asthmatics
with exacerbation risk in the persistent troublesome wheez-
ing group [70].
In a population-based longitudinal cohort that en-
rolled 1,650 preschool children in Leicestershire, United
Kingdom, early life wheeze and atopy data were used for
latent class analysis [71]. The three wheeze and two cough
phenotypes identified from early life data were assessed
for associations with school age respiratory outcomes. The
atopic persistent wheezers from early life had highest rates
of current or frequent wheeze at ages 8-13. These authors
identified a validation cohort of 6970 children born in a
different county of the United Kingdom, for whom atopy
and respiratory assessments were available at ages 8–13 in
approximately 900. Latent class analyses revealed five
groups with very similar characteristics to the groups seen
in the original cohort [72].
Unbiased analyses from longitudinal cohorts indeed
complement those of the cross-sectional cohorts. Despite
slight differences among the clusters in each cohort,
these unsupervised analyses ultimately identify clearly
that asthma phenotypes vary by atopy, age of wheeze
onset, clinical and physiologic characteristics. The stability
of these clusters into adulthood is not well known, however,
and the potential for progression from milder asthma
to more severe disease, or vice versa, needs further
elucidation.
Conclusion
We can easily recognize the clinical syndrome of asthma,
presenting as symptoms of reversible airflow obstruction
with airway hyper-reactivity and inflammation. More
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severe asthma is associated with exacerbations that cause
a significant degree of morbidity and even mortality.
However, the incident factors, pathogenesis, prognosis,
and treatment of asthma remain incompletely under-
stood. Utilizing measurable characteristics of asthmatic
patients, including demographic, physiologic, and biologic
markers, can identify meaningful phenotypic categories of
asthma. These phenotypes, while providing a helpful albeit
partial understanding of disease state, can be further lever-
aged toward endotypic characterization, with the ultimate
goals of identifying preventative strategies and im-
proving precision therapeutics targeted toward an
individual’s disease.
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